Tumor Stroma Articles & Analysis
3 articles found
The catabolism of this structure causes Lys-SMC-DM1 to become the main tumor metabolite. Furthermore, drugs linked to this linker usually cannot exert bystander effect because the released catabolites are less permeable. ...
At present, 15 ADCs have been approved globally for hematological malignancies and solid tumors. In addition, more than 100 ADC drug candidates are currently under clinical investigation. ...
Other types of ADC Despite its efficacy, most ADCs targeting solid tumors have not progressed beyond phase 2 clinical trials, suggesting that other parameters need to be optimized in order to reach the market. ...